TXMD NASDAQ
TherapeuticsMD, Inc.
1W: -2.4%
1M: -11.5%
3M: +1.5%
YTD: +21.2%
1Y: +88.7%
3Y: -33.8%
5Y: -94.4%
$2.05
+0.02 (+0.99%)
Weekly Expected Move ±4.3%
$2
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
19 relationships17
As Filer
counterparties named
2
As Counterparty
mentioned by others
3
Rel. Types
2022-03-07
Earliest Filing
2023-05-05
Latest Filing
investor: 6
partner: 6
acquirer: 5
Counterparties (Filed by TXMD)
17 relationshipsCompanies named in TXMD's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Rubric Capital Management LP | — | investor | Subscription agreement for up to 5,000,000 shares of common stock at an aggregate price of up to $5,000,000. | 2023-05-05 | View |
| Mayne Pharma LLC | — | partner | Exclusive licensee and asset purchaser in a transaction involving TherapeuticsMD's products and intellectual property. | 2023-01-03 | View |
| Mayne Pharma Group Limited | MYX | partner | Parent company of Mayne Pharma LLC, an Australian public company. | 2023-01-03 | View |
| Rubric Capital Management LP | — | investor | Affiliate of the Company that received a make-whole payment upon redemption of Series A Preferred Stock. | 2023-01-03 | View |
| Mayne Pharma LLC | — | partner | Exclusive licensee and asset purchaser for Imvexxy, Bijuva, and Annovera products | 2022-12-05 | View |
| Mayne Pharma Group Limited | MYX | partner | Parent company of Mayne Pharma LLC | 2022-12-05 | View |
| Rubric Capital Management LP | — | investor | Investor in private placement offering of Series A Preferred Stock | 2022-10-31 | View |
| Rubric Capital Management LP | — | investor | Investor in private placement offering of Series A Preferred Stock | 2022-10-03 | View |
| Athene Parent, Inc. | — | acquirer | Parent company acquiring TherapeuticsMD, Inc. in a cash tender offer and merger. | 2022-05-31 | View |
| Athene Merger Sub, Inc. | — | acquirer | Wholly owned subsidiary of Athene Parent, Inc. executing the merger and tender offer. | 2022-05-31 | View |
| EW Healthcare Partners | — | investor | Investment fund advisor providing equity commitment to fund the merger. | 2022-05-31 | View |
| EW Healthcare Partners Fund 2, L.P. | — | investor | Delaware limited partnership committing to provide equity contribution for the merger. | 2022-05-31 | View |
| VitaMedMD, LLC | — | partner | Subsidiary party to the Financing Agreement as a guarantor. | 2022-05-31 | View |
| BocagreenMD, Inc. | — | partner | Subsidiary party to the Financing Agreement as a guarantor. | 2022-05-31 | View |
| GoodRx Holdings, Inc. | GDRX | acquirer | Acquired vitaCare Prescription Services, Inc. from TherapeuticsMD, Inc. for approximately $150 million in cash. | 2022-04-20 | View |
| GoodRx, Inc. | GDRX | acquirer | Wholly-owned subsidiary of GoodRx Holdings, Inc. that acquired vitaCare Prescription Services, Inc. | 2022-04-20 | View |
| GoodRx Holdings, Inc. | GDRX | acquirer | Acquired vitaCare Prescription Services, Inc. from TherapeuticsMD, Inc. | 2022-03-10 | View |
Mentioned As Counterparty
2 mentionsOther companies that named TXMD in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-11 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-05-12 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-03-30 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-01-21 | Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits | View | |
| 2025-12-16 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-11-13 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-08-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-05-13 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-04-09 | Other Events | View | |
| 2025-03-27 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-12-05 | Submission of Matters to a Vote of Security Holders | View | |
| 2024-11-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-09-20 | Shareholder Nominations | View | |
| 2024-08-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-05-10 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-03-29 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2023-11-14 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2023-08-18 | Entry into Material Definitive Agreement; Departure/Election of Directors; Appointment of Officers | Agreement | View |
| 2023-08-14 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2023-07-10 | Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR